Treatment of ischemic optic neuropathy

Seminars in Ophthalmology

Volumn 17, Issue 1, 2002, Pages 39-46

  Arnold, Anthony C ^a   Levin, Leonard A ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

Corticosteroids; Ischemic optic neuropathy; Neuroprotection; Optic nerve regeneration; Thrombolysis

Indexed keywords

21 AMINOSTEROID; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; CARBIDOPA PLUS LEVODOPA; CATALASE; CLONIDINE; CORTICOSTEROID; FIBRINOLYTIC AGENT; HEPARIN; LEVODOPA; METHOTREXATE; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN; PHENYTOIN; REACTIVE OXYGEN METABOLITE; TIRILAZAD; VASODILATOR AGENT;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; BRAIN PSEUDOTUMOR; CENTRAL RETINA ARTERY OCCLUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DECOMPRESSION SURGERY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENZYME ACTIVITY; FIBRINOLYTIC THERAPY; HUMAN; HYPERBARIC OXYGEN; ISCHEMIC OPTIC NEUROPATHY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPINAL CORD INJURY; STROKE; TEMPORAL ARTERITIS; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM;

ADRENAL CORTEX HORMONES; DECOMPRESSION, SURGICAL; HUMANS; HYPERBARIC OXYGENATION; OPTIC NEUROPATHY, ISCHEMIC;

EID: 0036492314     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.1076/soph.17.1.39.10292     Document Type: Review

References (85)

1. Pathology of ischaemic optic neuropathy
2. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis
3. Visual morbidity in giant cell arteritis
4. Visual prognosis in giant cell arteritis
5. Combined treatment of giant-cell arteritis with methotrexate and prednisone: A randomized, double-blind, placebo-controlled trial
6. The adjuvant use of optic nerve sheath fenestration in biopsy proven temporal arteritis
7. Systemic lysis therapy in retinal vascular occlusions
8. Selective thrombolysis of central retinal artery occlusion without long-term systemic heparinization
9. Treatment of radiation-induced nervous system injury with heparin and warfarin
10. Neurologic manifestation of Horton's Disease. Value of heparin therapy
11. Anterior ischemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management
12. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy
13. Microvascular study of the retrolaminar optic nerve in man: The possible significance in anterior ischemic optic neuropathy
14. Les pseudo-papillites d'origin vasculaire
15. Acute optic neuropathy. Treatment with diphenylhydantoin
16. Norepinephrine therapy of ischemic optic neuropathy
17. Ischaemic papillopathy: Clinical and fluorescein angiographic review of forty cases
18. Visual field defects in anterior ischemic optic neuropathy
19. The effects of hyperbaric oxygen on retinal arterial occlusion
20. Hyperbaric oxygen in the treatment of radiation-induced optic neuropathy
21. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy
22. Optic nerve sheath decompression may improve the progressive form of ischemic optic neuropathy
23. Optic nerve sheath decompression for the treatment of progressive nonarteritic ischemic optic neuropathy
24. Optic nerve sheath decompression for nonarteritic anterior ischemic optic neuropathy improves multiple visual function measurements
25. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful
26. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial
27. Levodopa may improve vision loss in recent-onset nonarteritic anterior ischemic optic neuropathy
28. Does levodopa improve visual function in NAION? (Letter to the Editor)
29. Does levodopa improve visual function in NAION? (Letter to the Editor)
30. Treatment of traumatic optic neuropathy with corticosteroids
31. Traumatic optic neuropathy
32. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury
33. Effect of lipid peroxidation inhibition on retinal ganglion cell death
34. New therapies for optic neuropathies: Development in experimental models
35. Protection of human endothelial cells from oxidant injury by adenovirus-mediated transfer of the human catalase cDNA
36. Adenoviral gene therapy with catalase suppresses experimental optic neuritis
37. "Axogenic" and "somagenic" neurodegenerative diseases: Definitions and therapeutic implications
38. Pathophysiology of ischemic cell death: I. Time of onset of irreversible damage; importance of the different components of the ischemic insult
39. Central retinal artery occlusion and retinal tolerance time
40. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush
41. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells
42. Neuroprotective therapy
43. Neuroprotection for acute stroke: Making clinical trials work
44. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study
45. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study
46. Slowly progressive ischemic optic neuropathy. A clinicopathologic case report
47. The pattern of optic nerve fiber loss in anterior ischemic optic neuropathy
48. Apoptosis of retinal ganglion cells in anterior ischemic optic neuropathy
49. Histopathologic studies of ischemic optic neuropathy
50. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma
51. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats
52. Chronology of optic nerve head and retinal responses to elevated intraocular pressure
53. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. A quantitative in vivo study
54. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration
55. Retinal ganglion cell death induced by retinal ischemia. Neuroprotective effects of two alpha-2 agonists
56. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage
57. An investigation into the potential mechanisms underlying the neuroprotective effect of clonidine in the retina
58. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent
59. Betaxolol, a beta(1)- adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: Comparison with other beta-adrenoceptor antagonists
60. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA
61. Vitreous concentration of topically applied brimonidine tartrate 0.2%
62. Molecular basis of glutamate toxicity in retinal ganglion cells
63. Experimental induction of retinal ganglion cell death in adult mice
64. Factors affecting the survival of cat retinal ganglion cells after optic nerve injury
65. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey
66. Expression of the growth-associated protein GAP-43 in adult rat retinal ganglion cells following axon injury
67. Expression of ceruloplasmin in the retina: Induction after retinal ganglion cell axotomy
68. Identification of bcl-2 family genes in the rat retina
69. Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury
70. Activation of caspase-3 in axotomized rat retinal ganglion cells in vivo
71. Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats
72. Retinal ganglion cell loss after the period of naturally occurring cell death in bcl-2-/- mice
73. Expression of c-Jun protein in degenerating retinal ganglion cells after optic nerve lesion in the rat
74. Up-regulation of Bax protein in degenerating retinal ganglion cells precedes apoptotic cell death after optic nerve lesion in the rat
75. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis
76. Apoptosis in adult retinal ganglion cells after axotomy
77. NAION as a model disease for testing neuroprotective interventions-The BRAION Multicenter Study
78. Does brimonidine tartrate help NAION?
79. st century: LVIII Edward Jackson Memorial Lecture
80. Functional performance of the regenerating visual system
81. Aspirin reduces the incidence of second eye NAION: A restrospective study
82. Role of aspirin in reducing the frequency of second eye involvement in patients with nonarteritic anterior ischaemic optic neuropathy
83. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy
84. Role of aspirin in reducing the frequency of second eye involvement in patients with nonarteritic anterior ischemic optic neuropathy (Letter to the Editor)
85. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy